AccuMetab™ Human CYP3A7 Enzyme, Catalytically Active

CAT#: ITS-0426-YL12
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP3A7 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
As the predominant Phase I metabolizing enzyme in the fetal liver, CYP3A7 undergoes rapid downregulation shortly after birth. Testing against this isoform is vital for pediatric drug development, understanding fetal drug exposure, and assessing the teratogenic potential of maternal medications.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Mimics fetal hepatic drug clearance; Mandatory for pediatric and teratogenicity screening
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI); Toxicology
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry